Reference health

Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy

https://doi.org/10.1016/j.jconrel.2019.06.031

45/45 checkable references clean · checked 2026-07-22

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 45 checked references that resolve

resolves10.1158/0008-5472.CAN-14-1428

Impact of Metabolic Heterogeneity on Tumor Growth, Invasion, and Treatment Outcomes

resolves10.1016/j.addr.2015.01.002

Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity

resolves10.1038/s41467-018-03473-9

Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer

resolves10.1002/adfm.201900004

Tumor Microenvironment Responsive Drug‐Dye‐Peptide Nanoassembly for Enhanced Tumor‐Targeting, Penetration, and Photo‐Chemo‐Immunotherapy

resolves10.1002/adfm.201701255

Hydroxyl‐Rich Polycation Brushed Multifunctional Rare‐Earth‐Gold Core–Shell Nanorods for Versatile Therapy Platforms

resolves10.1002/adma.201402996

Immunological Responses Triggered by Photothermal Therapy with Carbon Nanotubes in Combination with Anti‐CTLA‐4 Therapy to Inhibit Cancer Metastasis

resolves10.1016/j.coph.2013.05.017

Tumour-associated macrophages and cancer

resolves10.1073/pnas.2232479100

Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance

resolves10.1021/acsami.7b01365

“One-for-All”-Type, Biodegradable Prussian Blue/Manganese Dioxide Hybrid Nanocrystal for Trimodal Imaging-Guided Photothermal Therapy and Oxygen Regulation of Breast Cancer

resolves10.7150/thno.7869

Mesoporous Magnetic Gold “Nanoclusters” as Theranostic Carrier for Chemo-Photothermal Co-therapy of Breast Cancer

resolves10.1021/acsami.7b17022

Erythrocyte-Membrane-Coated Prussian Blue/Manganese Dioxide Nanoparticles as H2O2-Responsive Oxygen Generators To Enhance Cancer Chemotherapy/Photothermal Therapy

resolves10.1021/acsami.7b14705

Porous Au@Pt Nanoparticles: Therapeutic Platform for Tumor Chemo-Photothermal Co-Therapy and Alleviating Doxorubicin-Induced Oxidative Damage

resolves10.1056/NEJMoa1200694

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

resolves10.1016/j.cell.2015.03.030

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

resolves10.1053/j.seminoncol.2017.06.007

Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable

resolves10.1080/13543776.2018.1512706

A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018)

resolves10.1021/acsnano.8b00204

Laser Immunotherapy in Combination with Perdurable PD-1 Blocking for the Treatment of Metastatic Tumors

resolves10.1016/j.jconrel.2018.04.002

Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors

resolves10.1038/nature14011

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

resolves10.1093/intimm/dxu095

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

resolves10.1002/anie.201506225

Blocking of the PD‐1/PD‐L1 Interaction by a <scp>D</scp>‐Peptide Antagonist for Cancer Immunotherapy

resolves10.1016/j.biomaterials.2017.11.048

Nanoantagonists with nanophase-segregated surfaces for improved cancer immunotherapy

resolves10.1016/j.cclet.2018.03.033

Enzymatic clickable functionalization of peptides via computationally engineered peptide amidase

resolves10.1002/adfm.201802227

Acid‐Responsive Transferrin Dissociation and GLUT Mediated Exocytosis for Increased Blood–Brain Barrier Transcytosis and Programmed Glioma Targeting Delivery

resolves10.1080/02652048.2017.1343873

Matrix metalloproteases-responsive nanomaterials for tumor targeting diagnosis and treatment

resolves10.1002/adma.201501502

A Peptide‐Network Weaved Nanoplatform with Tumor Microenvironment Responsiveness and Deep Tissue Penetration Capability for Cancer Therapy

resolves10.1016/j.cclet.2018.02.010

Bone-targeting melphalan prodrug with tumor-microenvironment sensitivity: Synthesis, in vitro and in vivo evaluation

resolves10.1002/adma.201200454

Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles

resolves10.1039/C7TB01268C

In vivo self-assembly induced retention of gold nanoparticles for enhanced photothermal tumor treatment

resolves10.1016/j.celrep.2017.02.011

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

resolves10.1016/j.biomaterials.2017.06.007

Targeting epithelial-mesenchymal transition: Metal organic network nano-complexes for preventing tumor metastasis

resolves10.1158/0008-5472.CAN-07-6752

Mitochondrial/Cell-Surface Protein p32/gC1qR as a Molecular Target in Tumor Cells and Tumor Stroma

resolves10.1021/acs.molpharmaceut.7b00801

Structure Reconstruction of LyP-1: Lc(LyP-1) Coupling by Amide Bond Inspires the Brain Metastatic Tumor Targeted Drug Delivery

resolves10.1002/anie.201104507

X‐Ray Computed Tomography Imaging of Breast Cancer by using Targeted Peptide‐Labeled Bismuth Sulfide Nanoparticles

resolves10.1016/j.cclet.2019.02.019

LyP-1 peptide-functionalized gold nanoprisms for SERRS imaging and tumor growth suppressing by PTT induced-hyperthermia

resolves10.1021/acsami.8b05876

Photothermal-Activatable Fe3O4 Superparticle Nanodrug Carriers with PD-L1 Immune Checkpoint Blockade for Anti-metastatic Cancer Immunotherapy

resolves10.1021/acs.nanolett.8b01071

Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy

resolves10.1038/ncomms13193

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy

resolves10.1126/scitranslmed.3003689

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

resolves10.1126/scitranslmed.3006504

Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

resolves10.1111/j.0105-2896.2006.00423.x

Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation

resolves10.1021/acsnano.5b02014

Antigen-Loaded Upconversion Nanoparticles for Dendritic Cell Stimulation, Tracking, and Vaccination in Dendritic Cell-Based Immunotherapy

resolves10.1172/JCI68395

IL-12p70–producing patient DC vaccine elicits Tc1-polarized immunity

resolves10.1016/S0735-1097(18)30957-4

MAST CELLS MODULATE THE PATHOGENESIS OF LEPTIN-INDUCED VENTRICULAR ARRHYTHMIAS IN CANINE

resolves10.1021/acsnano.6b05419

Near-Infrared Emission CuInS/ZnS Quantum Dots: All-in-One Theranostic Nanomedicines with Intrinsic Fluorescence/Photoacoustic Imaging for Tumor Phototherapy

The 5 references without a DOI — listed, not checked

no DOI — not checkedPhotosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy

no DOI — not checkedTailoring biomaterials for cancer immunotherapy: emerging trends and future outlook

no DOI — not checkedImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

no DOI — not checkedDevelopment of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy

no DOI — not checkedAge-related changes in type 1 and type 2 cytokine production in humans

What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

view as graph · paper page

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1016/j.jconrel.2019.06.031"><img src="https://citestamp.com/citestamped/10.1016/j.jconrel.2019.06.031/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>

[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1016/j.jconrel.2019.06.031/badge.svg)](https://citestamp.com/citestamped/10.1016/j.jconrel.2019.06.031)